197 related articles for article (PubMed ID: 38331870)
21. Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies.
Howard AJ; Concepcion I; Wang AX; Hamadeh IS; Hultcrantz M; Mailankody S; Tan C; Korde N; Lesokhin AM; Hassoun H; Shah UA; Maclachlan KH; Rajeeve S; Landau HJ; Scordo M; Shah GL; Lahoud OB; Chung DJ; Giralt S; Usmani SZ; Firestone RS
Blood Adv; 2024 Jun; 8(12):3246-3253. PubMed ID: 38621239
[TBL] [Abstract][Full Text] [Related]
22. Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?
Martino M; Gamberi B; Antonioli E; Aquino S; Della Pepa R; Malerba L; Mangiacavalli S; Pezzatti S; Bringhen S; Zamagni E
Expert Rev Hematol; 2024 May; ():1-16. PubMed ID: 38770902
[TBL] [Abstract][Full Text] [Related]
23. Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma.
Apollonio B; Spada F; Petrov N; Cozzetto D; Papazoglou D; Jarvis P; Kannambath S; Terranova-Barberio M; Amini RM; Enblad G; Graham C; Benjamin R; Phillips E; Ellis R; Nuamah R; Saqi M; Calado DP; Rosenquist R; Sutton LA; Salisbury J; Zacharioudakis G; Vardi A; Hagner PR; Gandhi AK; Bacac M; Claus C; Umana P; Jarrett RF; Klein C; Deutsch A; Ramsay AG
J Clin Invest; 2023 Jul; 133(13):. PubMed ID: 37219943
[TBL] [Abstract][Full Text] [Related]
24. Sequencing of anti-CD19 therapies in the management of diffuse large B-cell lymphoma.
Lownik J; Boiarsky J; Birhiray R; Merchant A; Mead M
Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38661647
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic transplantation after immunotherapy for relapsed/refractory non-Hodgkin lymphoma: a comparison with a historical cohort.
Mariotti J; Zucchinetti C; Giordano L; De Philippis C; Mannina D; Sarina B; Taurino D; Carbon R; Santoro A; Bramanti S
Cytotherapy; 2024 May; ():. PubMed ID: 38775776
[TBL] [Abstract][Full Text] [Related]
26. CAR T-cell therapy: A collaboration between authorized treatment centers and community oncologists.
Bishop MR; Kay GE
Semin Oncol; 2024 Feb; ():. PubMed ID: 38531760
[TBL] [Abstract][Full Text] [Related]
27. A pivotal decade for bispecific antibodies?
Surowka M; Klein C
MAbs; 2024; 16(1):2321635. PubMed ID: 38465614
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma.
Crochet G; Iacoboni G; Couturier A; Bachy E; Iraola-Truchuelo J; Gastinne T; Cartron G; Fradon T; Lesne B; Kwon M; Gounot R; Martínez-Cibrian N; Castilla-Llorente C; Abrisqueta P; Guerreiro M; Sarkozy C; Aspa-Cilleruelo JM; Camus V; Guidez S; Chauchet A; Deconinck E; Bouabdallah K; Bosch F; Barba P; Morschhauser F; Houot R
Blood; 2024 Apr; ():. PubMed ID: 38657242
[TBL] [Abstract][Full Text] [Related]
29. Bispecific antibodies: Potential immunotherapies for HIV treatment.
Fabozzi G; Pegu A; Koup RA; Petrovas C
Methods; 2019 Feb; 154():118-124. PubMed ID: 30352254
[TBL] [Abstract][Full Text] [Related]
30. Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma.
Song YQ; Zhang HL; Huang HQ; Zhang QY; Jing HM; Wang C; Wu C; Li DH; Dai Y; Humphrey K; Zhu J
Haematologica; 2024 Apr; 109(4):1269-1273. PubMed ID: 37855035
[No Abstract] [Full Text] [Related]
31. Mouse models of diffuse large B cell lymphoma.
Tabatabai A; Arora A; Höfmann S; Jauch M; von Tresckow B; Hansen J; Flümann R; Jachimowicz RD; Klein S; Reinhardt HC; Knittel G
Front Immunol; 2023; 14():1313371. PubMed ID: 38124747
[TBL] [Abstract][Full Text] [Related]
32. Innovative Combinations, Cellular Therapies and Bispecific Antibodies for Chronic Lymphocytic Leukemia: A Narrative Review.
Visentin A; Frazzetto S; Trentin L; Chiarenza A
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610967
[TBL] [Abstract][Full Text] [Related]
33. Disrupting B and T cell Collaboration in Autoimmune Disease: T cell engagers versus CAR T cell therapy?
Shah K; Leandro M; Cragg M; Kollert F; Schuler F; Klein C; Reddy V
Clin Exp Immunol; 2024 Apr; ():. PubMed ID: 38642912
[TBL] [Abstract][Full Text] [Related]
34. Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives.
Heitmann JS; Pfluegler M; Jung G; Salih HR
Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33535627
[TBL] [Abstract][Full Text] [Related]
35. Geometric Antibody Engineering Reveals the Spatial Factor on the Efficacy of Bispecific T Cell Engagers.
Zhang Y; Yang Z; Saimi D; Shen X; Ye J; Yu B; Pefaur N; Scheer JM; Nixon AE; Chen Z
ACS Chem Biol; 2024 Apr; 19(4):916-925. PubMed ID: 38491942
[TBL] [Abstract][Full Text] [Related]
36. A new CAR takes a test drive in DLBCL.
Abramson JS
Blood; 2023 May; 141(20):2410-2411. PubMed ID: 37200062
[No Abstract] [Full Text] [Related]
37. Relapse after glofitamab, a novel unmet medical need with high rates of CD20 loss.
Carlo-Stella C
Br J Haematol; 2024 May; ():. PubMed ID: 38813657
[TBL] [Abstract][Full Text] [Related]
38. Relapse after glofitamab has a poor prognosis and rates of CD20 loss are high.
Grigg S; Minson A; Prins E; Dickinson MJ
Br J Haematol; 2024 May; ():. PubMed ID: 38720530
[TBL] [Abstract][Full Text] [Related]
39. [Glofitamab in relapsed and/or refractory diffuse large B cell lymphoma after at least two lines of treatment].
Daguerre V; Croizier C
Bull Cancer; 2024 Jun; ():. PubMed ID: 38876895
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
